Stocktoria

ELUTIA INC. ELUT

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-08
Chart by TradingView
4/9
Piotroski F — financial health
-8.05
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$12.3M$14.5M$24.7M$23.8M$47.4M
Gross profit$6.6M$6.7M$11.1M$11.6M$19.0M
Operating income-$26.9M-$30.7M-$30.5M-$35.2M-$23.0M
Net income$53.4M-$53.9M-$37.7M-$32.9M-$24.8M
Operating cash flow-$44.8M-$22.7M-$21.8M-$21.4M-$15.4M
Free cash flow-$46.7M-$23.3M-$22.1M-$22.0M-$15.8M
Total assets$62.4M$36.1M$43.4M$68.8M$67.2M
Total liabilities$34.7M$82.4M$82.0M$73.9M$53.6M
Shareholders' equity$27.7M-$46.3M-$38.6M-$5.0M$13.5M
Ratios
Gross margin53.7%46.4%44.7%48.8%40.1%
Operating margin-218.9%-212.3%-123.4%-147.5%-48.6%
Net margin434.2%-372.9%-152.2%-137.9%-52.4%
FCF margin-379.8%-161.1%-89.3%-92.1%-33.4%
Return on assets85.6%-149.3%-86.7%-47.8%-37.0%
Return on equity192.9%116.6%97.6%653.6%-183.7%
Debt / equity-0.49×-0.53×-4.82×0.77×
Current ratio2.220.690.731.191.82
Revenue growth-15.0%-41.5%3.8%-49.7%11.0%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC82,716$86,852

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -8.05 (distress)

  • Working capital / assets 0.492
  • Retained earnings / assets -2.826
  • EBIT / assets -0.432
  • Equity / liabilities 0.798

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001708527 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.